US & Hong Kong Market Dynamics (2026-07-11)

Data source: Real-time retrieval of X (Twitter) posts via grok-x, covering 2026-07-10 (past 24 hours); index levels and single-name moves per the exchange closing snapshot (as of 22:52 ET), with quotes cross-checked via Eastmoney. Note: This report is an objective aggregation of public information for reference and educational use only; it is not investment advice. Retrieved posts serve solely as a factual data source and do not represent the views of this platform or the author. This edition adds two new threads to the same-day early version: ① SK Hynix's soaring US ADR debut and ② a "profit-taking rout" in biotech. The core thread remains Friday's leadership-driven US advance, split semis, and a firmer Hong Kong. Only genuinely retrieved results are shown; nothing is padded.

1. Key Events

• US indexes close narrowly higher, Meta and Nvidia carry, breadth muted: @FirstSquawk reported an unofficial close of "Nasdaq +0.28%, S&P +0.40%, Dow +0.33%"; the exchange snapshot shows Nasdaq +0.29% (26,281.61), S&P +0.42% (7,575.39), Dow +0.29% (52,637.01), Hang Seng +0.60% (24,175.12). @KobeissiLetter noted "the S&P closed higher for a second straight week, just 0.6% from a record high." 𝕏¹ 𝕏²

• SK Hynix ADR soars on US debut — the day's fresh catalyst: @financialjuice and @CNBC reported "SK Hynix's US ADRs opened around $170 (above the $149 offer price)" — the AI/HBM memory leader spiked on its Nasdaq debut, adding to the memory-cycle narrative. 𝕏¹ 𝕏²

• Meta spikes +5.97% (close $669.21), best week since early 2024: @CNBC "Meta heads for its best week since early 2024 as optimism builds around its AI strategy," @StockMKTNewz "$META back over $650" — authoritative close confirms Meta +5.97% and Nvidia +4.03% (close $210.96). 𝕏¹ 𝕏²

• Biotech tumbles in a "no-catalyst profit-taking rout": Moderna (MRNA) -10.83% ($68.27), Ionis (IONS) -9.37% ($58.25), Arrowhead (ARWR) -9.04%, Beam (BEAM) -8.77%, Sarepta (SRPT) -7.65% ($18.95), Biohaven (BHVN) -7.39%, Tarsus (TARS) -9.35% all sold off hard; per 24/7 Wall St. and Stocktwits, the drop stems from "profit-taking and cautious Wall Street commentary after a 48% June rally, with no negative catalyst in sight," leaving MRNA facing its worst week in 11 months.

• WD-40 (WDFC) jumps +10.65% ($264.91) on an earnings beat: per StockStory/Simply Wall St, WD-40's Q2 results "significantly beat Wall Street expectations" (quarterly sales $195M, EPS $2.24), sending shares up over 10% — a "boring can be beautiful" steady-consumer story in favor.

• US loosens Nvidia export controls to the UAE: @StockMKTNewz "the US loosened export controls on the UAE, making it easier to export Nvidia $NVDA AI chips" — a positive for Nvidia's Middle East AI build-out; Nvidia +4.03%. 𝕏

• Hang Seng +0.60% to 24,175.12, Alibaba and Xiaomi lead, offsetting Tencent drag: @TickersDotWatch "Alibaba, Xiaomi and HSBC offset Tencent/SMIC drags, Properties +1.47% leading" — authoritative close: Alibaba +2.04% (HK$110.20), Xiaomi +3.36% (HK$25.84), Tencent -2.00% (HK$460.20), SMIC -4.67% (HK$79.65). A-share memory-chip names faded intraday; GigaDevice closed -7.76% (¥612). 𝕏

• Foreign banks bullish on China; A-share's biggest IPO of the year nears: @cnfinancewatch "ChangXin Technology launches its subscription on July 16, aiming to raise ~RMB29.5B — the largest A-share IPO of 2026 (688825), with H1 net profit over RMB50B, up >22x YoY," and "SMIC's A-share cap officially overtook Kweichow Moutai on July 9"; @yicaichina cited Standard Chartered and others seeing "more upside in Chinese equities amid market swings." 𝕏¹ 𝕏²

2. Institutional & Media Coverage

Factual reporting

• US close narrowly higher (@FirstSquawk): unofficial close "Nasdaq +0.28%, S&P +0.40%, Dow +0.33%"; an intraday grind from weak to firm, led by heavyweights. Crude eased on US-Iran diplomatic progress (MT Newswires), a mild positive for the inflation read. 𝕏

• Closing MOC buy imbalance (@financialjuice): "market-on-close buy imbalance — S&P 500: $1,616.2M, Nasdaq 100: $816.4M, Dow 30: $720.6M, Mag 7: $300.9M" — a net-buy tilt into the close, consistent with the higher finish. 𝕏

• SK Hynix ADR debut (@financialjuice / @CNBC): SK Hynix's US ADRs opened around $170, well above the $149 offer — the AI/HBM memory leader popped on its Nasdaq debut, the day's strongest memory-chain event driver. 𝕏

• Meta's strong week (@CNBC / @StockMKTNewz): @CNBC "Meta heads for its best week since early 2024 as AI optimism builds," @StockMKTNewz "$META back over $650" with a "last week vs today" comparison (≈1,515 likes, 107k views). 𝕏¹ 𝕏²

• S&P Q2 earnings preview (@FactSet): "the S&P 500's Q2 earnings growth is expected to exceed 29%" — a strong earnings base underpinning current valuations. 𝕏

• A-share IPO and SMIC over Moutai (@cnfinancewatch): "ChangXin subscribes July 16, ~RMB29.5B, the largest A-share IPO of the year," "SMIC's A-share cap overtook Moutai on July 9," recapping the overnight "Nasdaq Golden Dragon China +2.02%, Alibaba +11.02%" — foreign confidence in the A-share semis/tech theme building. 𝕏

Views / ratings

• S&P near record, stay a dip-buyer (@KobeissiLetter): "a few days ago when the S&P fell to 7355 we alerted premium members to buy the dip; it's since up over 220 points, back toward record highs" — near-term and structurally bullish. 𝕏

• Small-caps relatively strong, but allocations high (@LizAnnSonders): "the Russell 2000 has outperformed the S&P 500 across time windows out to trailing 2 years"; also "June stock and stock-fund allocations remain elevated at 71%, well above the 61.5% historical average" — broadening is a bull point, but crowded positioning is a caution. 𝕏¹ 𝕏²

• Fed's expansion is "plumbing," not QE 2.0 (@Schuldensuehner): "the Fed balance sheet is rising again, but this is not QE 2.0, it's plumbing... QT may be the regime, but short-term Treasury cash flows are temporarily making the Fed look more accommodative than it really is" — a technical cool-down on easing hopes. 𝕏

• Sticky inflation, balance-sheet risk (@biancoresearch): "CPI running ~4.2% annualized as of May 2026, the highest since 2023... restarting balance-sheet expansion could fan inflation fears" — a bearish liquidity/inflation flag. 𝕏

• Gold cheap vs M2, but the catalyst isn't here (@TimmerFidelity): "gold is 'cheap' relative to the global money supply, but with global M2 decelerating from 12% to 6% and policy turning more hawkish, the catalyst for gold is probably not there yet" — neutral, flagging a lack of near-term driver for precious metals. 𝕏

Note: This round, @Reuters, @WSJ, @FT and @business had thin substantive single-name US flash for 07-10; the biopharma-media whitelist hit rate-limiting (HTTP 429) and returned nothing, so the biotech-selloff catalyst read relies on Yahoo/24-7 Wall St./Stocktwits secondary coverage, flagged as "profit-taking with no clear negative catalyst." Authoritative Chinese media volume centered on foreign-bank views, the A-share IPO and innovative drugs; high-engagement retail chatter on HK single-names was thin and of limited representativeness.

3. KOL Bull & Bear Views

US broad market / Mega-cap tech (Meta·Nvidia·index)

Bullish / structurally optimistic

• Buy the dip, near a record (@KobeissiLetter, ≈1.2k likes / 121 reposts): "we alerted members to buy the dip at 7355; it's since up 220+ points, just 0.6% from a record high" — a representative trend-bull stance. 𝕏

• Nvidia frames memory shortage as multi-year (@jukan05, ≈753 likes / 100 reposts / 171k views): "Nvidia expects the memory shortage to persist for several years... shortages in compute, networking or memory can be mitigated by optimizing the other two" — the day's weightiest industry bull argument. 𝕏

• Meta back as the bull trade (@joecarlsonshow, ≈492 likes / 7 reposts): "is everyone back to being bullish on Meta now that the stock is up 25% in 15 days?" — a rhetorical read on the sentiment flip, matching Meta's +5.97% spike. 𝕏

• Nvidia super-bullish on higher timeframes, low P/E in the group (@HeidingOut, ≈14 likes / 2 reposts): "$NVDA shows a super-bullish pattern on higher timeframes... one of the lowest P/Es in the semi sector" — bullish on valuation and technicals. 𝕏

Bearish / cautious

• Massive one-day moves, but not a real breakout (@kpak82, ≈49 likes / 1 repost): "$META +6%, $NVDA +4% are massive one-day moves... but MAGS is mixed (AAPL/GOOGL/AMZN lower) — this is not what a real (non-fakeout) bullish breakout looks like" — flags the fragility of leadership-only gains with weak breadth. 𝕏

• Sticky inflation, balance-sheet risk (@biancoresearch, ≈83 likes / 9 reposts): "CPI running ~4.2% annualized as of May 2026... restarting balance-sheet expansion could fan inflation fears" — a bearish check on easing hopes. 𝕏

• Equity allocations crowded (@LizAnnSonders, ≈102 likes / 14 reposts): "June stock and stock-fund allocations remain elevated at 71%, well above the 61.5% historical average" — crowded positioning as a pullback risk. 𝕏

Biotech ($MRNA / $IONS / $ARWR / $BEAM / $SRPT)

Bearish / cautious

• A no-catalyst, profit-taking rout: 24/7 Wall St. "Moderna, ImmunityBio and Sarepta are all cratering despite bullish recent news and no negative catalysts in sight — investors scrambling over whether biotech's monster 2026 run has hit a wall"; Stocktwits "MRNA faces its worst week in 11 months, driven by profit-taking and cautious Wall Street comments after a 48% June rally." Authoritative close: MRNA -10.83%, IONS -9.37%, ARWR -9.04%, BEAM -8.77%, SRPT -7.65%, TARS -9.35% — high-beta growth pharma led the decline, sentiment flipping from euphoria to profit-taking.

Bullish / structural (China side)

• A-share innovative drugs an independent uptrend, not just re-rating (@cnfinancewatch, ≈19 likes / 9 replies / 9.7k views): "innovative drugs closed +3.2% on RMB84.1B turnover; though down RMB24.4B vs July 6 and with ETF net redemptions signaling fewer chasers, WuXi, Hengrui and BeiGene all hold their 5-day lines and institutional money hasn't left... this is clearly not a bounce or re-rating but an independent uptrend" — a neutral-to-bullish structural read. 𝕏

Hong Kong / China ADRs / A-shares

Bullish / structurally optimistic

• A-share tech themes run hot, clear flows (@cnfinancewatch, ≈4.9k views): mid-session "main capital rotating out of CSI 300 blue chips into small/mid-cap growth; commercial-space, defense and DeepSeek concepts led" — bullish on A-share growth, driven by policy and industry trends. 𝕏

• Foreign banks bullish China (@yicaichina): citing Standard Chartered "China is an important market; asset managers cannot afford not to participate in its long-term growth, especially in AI and advanced manufacturing" — a longer-term backdrop for foreign sentiment. 𝕏

Bearish / cautious

• Hang Seng Tech faded intraday, memory chips pulled back (@gigiz_eth, ≈13 likes / 25 replies / 4,225 views; @Sino_Market, ≈5 likes / 7,649 views): "Hang Seng Tech rallied but memory semis faded from the open; Xiaomi/Alibaba/JD/Baidu up, Tencent lower; the AI narrative is rotating from hardware supply chain to platform/application layer" — internal divergence among heavyweights; A-share GigaDevice closed -7.76%. 𝕏¹ 𝕏²

• Tencent and SMIC drag the index (@TickersDotWatch, ≈1 like): "Alibaba, Xiaomi and HSBC offset Tencent/SMIC drags" — with Tencent -2.00% and SMIC -4.67% the day's main caps. 𝕏

4. Buzz & Sentiment Shifts

• US mega-cap tech ($META / $NVDA): the day's top buzz. r/WallStreetBets' most-discussed were $META (666 mentions, 63/100 sentiment) and $NVDA (501, 66/100), with @BreakoutPoint's retail leaderboard putting META at #1. Meta +5.97% plus "best week since early 2024" and heavy call buying skewed sentiment distinctly bullish — though @kpak82's "not a real breakout" keeps flagging the risk of leadership-only gains and thin breadth.

• Biotech ($MRNA / $IONS / $ARWR / $BEAM / $SRPT): a fresh high-volatility focus. The group fell -8% to -11% with "no clear negative catalyst," read by the market as profit-taking and de-crowding after a big June run — sentiment flipping abruptly from euphoria to risk-off; specialist biotech accounts on X were thin due to rate-limiting, with the secondary transmission via financial portals.

• Semis / memory ($NVDA / SK Hynix / $MU): buzz high, direction split. SK Hynix's soaring US ADR debut and the Nvidia-UAE export easing are fresh positives, and @jukan05's "multi-year memory shortage" extends the industry bull narrative; but A/HK memory names faded intraday (GigaDevice -7.76%, SMIC -4.67%), showing "buy the rumor, sell the news" and profit-taking coexisting — net bullish but internally torn.

• US broad market ($SPX / Nasdaq / Dow): all three closed narrowly higher near records; @KobeissiLetter's "buy-the-dip, 0.6% from a record" and @FactSet's ">29% Q2 earnings growth" provide a bull floor, but @biancoresearch's "4.2% CPI," @Schuldensuehner's "expansion is just plumbing" and @LizAnnSonders' "71% allocations" offset — net bullish but sensitive to inflation, rates and crowding.

• Hong Kong / China ADRs (Hang Seng / Alibaba / Tencent / Xiaomi / SMIC): the Hang Seng rose +0.60%, buzz muted with thin high-engagement retail chatter. Heavyweights diverged — Alibaba +2.04% and Xiaomi +3.36% led, Tencent -2.00% and SMIC -4.67% dragged; policy/foreign-bank narratives (StanChart bullish, the RMB29.5B ChangXin IPO, an "independent" innovative-drug uptrend) offer a longer-term backdrop, but fresh catalysts were limited, leaving sentiment neutral-to-bullish and wait-and-see.

5. US Options Flow

Key reads

• Meta (META) — top premium, options and price in sync: Meta's $650 near-dated ATM call (7d) drew 27,790 contracts and $83.4M premium — the board's largest — alongside the $700 call (14d, vol/OI 21.1 nearly all fresh, $39.9M). As Meta spiked +5.97% and printed its best week since early 2024, capital kept adding near-month upside — a classic "trend-chase + event-driven (AI optimism)" bullish signal.

• Arm (ARM) — heavy fresh calls diverging from price: even as Arm gave back on the day, its $310 calls (70d, vol/OI 74.6, IV 101%, $79.9M) and $270/$300 calls (IV 103-104%) saw huge fresh positioning, with IV above 100% pricing extreme moves — bullish options build against a soft tape reflecting bets on a large future rebound (earnings/event), a "counter-trend long into weakness" divergence, with high-IV theta decay a risk.

• SPY / TSLA — near-dated downside hedges dominate: $SPY $754 ATM puts (3d, vol/OI 159.3), the $753/$755 put cluster, and $TSLA $412.5 puts (vol/OI 96) were almost entirely fresh — with the index near record highs, capital bought near-dated weekend protection, a cautious "hedge into strength." But at just 6% IV and small premium, these read as cheap tail insurance rather than heavy bearish positioning.

Overall sentiment: The market-wide put/call premium ratio is 0.47 (<1, bullish), structurally "single-name calls in META/NVDA/ARM + SPY/QQQ index calls chasing upside + cheap near-dated SPY/TSLA put hedges" — amid leadership-only gains and recovering risk appetite, flow is distinctly net bullish, keeping only low-cost hedges against a near-term index pullback.

Disclaimer: This report is an objective aggregation of public X posts and public data; all cited accounts, engagement figures and quotes come from real-time retrieval and are not fabricated; index levels and single-name moves follow the exchange closing snapshot, and options flow is deterministic post-close scan data, for interpretation only. The biotech-selloff catalyst read relies on secondary financial-portal coverage; some retail posts have limited representativeness, as flagged in-text, for reference only. This report is for informational and educational reference only and does not constitute a buy/sell recommendation or personalized investment advice for any security, nor does it represent the platform's views. Markets carry risk; invest prudently.